{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:54:47Z","timestamp":1765486487770,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jval.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T01:21:34Z","timestamp":1602552094000},"page":"86-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?"],"prefix":"10.1016","volume":"24","author":[{"given":"Josephine","family":"Mauskopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Masaquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jval.2020.06.018_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jval.2018.08.005","article-title":"Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report","volume":"21","author":"Mauskopf","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2020.06.018_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","article-title":"Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community","volume":"34","author":"Ultsch","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"51","key":"10.1016\/j.jval.2020.06.018_bib4","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1016\/j.vaccine.2013.08.008","article-title":"The role of health economic analyses in vaccine decision making","volume":"31","author":"Black","year":"2013","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.jval.2020.06.018_bib5","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.vaccine.2007.04.070","article-title":"Do we fully understand the economic value of vaccines?","volume":"25","author":"Drummond","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.06.018_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhealeco.2014.02.001","article-title":"The social value of mortality risk reduction: VSL versus the social welfare function approach","volume":"35","author":"Adler","year":"2014","journal-title":"J\u00a0Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.06.018_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOP.0b013e32832c9668","article-title":"Neisseria meningitidis: epidemiology, treatment and prevention in adolescents","volume":"21","author":"Brigham","year":"2009","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"10.1016\/j.jval.2020.06.018_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.jval.2020.06.018_bib10","article-title":"Meningococcal serogroups and surveillance: a systematic review and survey","volume":"9","author":"Peterson","year":"2019","journal-title":"J\u00a0Glob Health"},{"issue":"2 suppl","key":"10.1016\/j.jval.2020.06.018_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.jval.2020.06.018_bib12","unstructured":"Centers for Disease Control and Prevention. Guidance for the evaluation of public health management of suspected outbreaks of meningococcal disease. Advisory Committee on Immunization Practice. Version 2.0. September 28, 2019. https:\/\/www.cdc.gov\/meningococcal\/downloads\/meningococcal-outbreak-guidance.pdf. Accessed January 16,\u00a02020."},{"issue":"16","key":"10.1016\/j.jval.2020.06.018_bib13","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004-2014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.jval.2020.06.018_bib14","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.10.029","article-title":"An analytical framework for immunization programs in Canada","volume":"23","author":"Erickson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.06.018_bib15","doi-asserted-by":"crossref","first-page":"h308","DOI":"10.1136\/bmj.h308","article-title":"Do we need a new approach for making vaccine recommendations?","volume":"350","author":"Crowcroft","year":"2015","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.1016\/j.jval.2020.06.018_bib16","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","article-title":"Moving beyond traditional valuation of vaccination: needs and opportunities","volume":"35","author":"Bloom","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jval.2020.06.018_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force Report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2020.06.018_bib18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jval.2020.06.018_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40273-016-0414-z","article-title":"Extended cost-effectiveness analysis for health policy assessment: a tutorial","volume":"34","author":"Verguet","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"suppl 5","key":"10.1016\/j.jval.2020.06.018_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1469-0691.2012.03977.x","article-title":"Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus","volume":"18","author":"Barnighausen","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.jval.2020.06.018_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142691","article-title":"Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: results from an extended cost-effectiveness analysis","volume":"10","author":"Johansson","year":"2015","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.jval.2020.06.018_bib22","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2020.06.018_bib23","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2020.06.018_bib24","first-page":"1912","article-title":"The value of risks to life and health","volume":"31","author":"Viscusi","year":"1993","journal-title":"J\u00a0Econ Lit"},{"issue":"2","key":"10.1016\/j.jval.2020.06.018_bib25","first-page":"266","article-title":"The market value of reducing cancer risk: hedonic housing prices with changing information","volume":"69","author":"Gayer","year":"2002","journal-title":"South Econ J"},{"issue":"2","key":"10.1016\/j.jval.2020.06.018_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1542\/peds.113.2.283","article-title":"Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine","volume":"113","author":"Prosser","year":"2004","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.jval.2020.06.018_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1014020027011","article-title":"Age, health and the willingness to pay for mortality risk reductions: a contingent valuation survey of Ontario residents","volume":"24","author":"Krupnick","year":"2002","journal-title":"J\u00a0Risk Uncertain"},{"issue":"39","key":"10.1016\/j.jval.2020.06.018_bib28","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1016\/j.vaccine.2014.07.003","article-title":"Valuing vaccines using value of statistical life measures","volume":"32","author":"Laxminarayan","year":"2014","journal-title":"Vaccine"},{"year":"2017","series-title":"Averting catastrophes that kill","author":"Martin","key":"10.1016\/j.jval.2020.06.018_bib29"},{"issue":"1","key":"10.1016\/j.jval.2020.06.018_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/bca.2015.3","article-title":"Reference-dependence effects in benefit assessment: beyond the WTA\u2013WTP dichotomy and WTA\u2013WTP ratios","volume":"6","author":"Viscusi","year":"2015","journal-title":"J\u00a0Benefit Cost Anal"},{"issue":"2","key":"10.1016\/j.jval.2020.06.018_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1017\/bca.2017.21","article-title":"Best estimate selection bias in the value of a statistical life","volume":"9","author":"Viscusi","year":"2018","journal-title":"J\u00a0Benefit Cost Anal"},{"issue":"1","key":"10.1016\/j.jval.2020.06.018_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12916-018-1130-7","article-title":"Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks","volume":"16","author":"Park","year":"2018","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.jval.2020.06.018_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2020.06.018_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00019053-200725020-00006","article-title":"Conjoint analysis of French and German parents\u2019 willingness to pay for meningococcal vaccine","volume":"25","author":"Bishai","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.jval.2020.06.018_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181073","article-title":"Adolescent values for immunisation programs in Australia: a discrete choice experiment","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jval.2020.06.018_bib36","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/INF.0000000000001512","article-title":"Cost-effectiveness comparison of monovalent C versus quadrivalent ACWY meningococcal conjugate vaccination in Canada","volume":"36","author":"De Wals","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jval.2020.06.018_bib37","doi-asserted-by":"crossref","first-page":"g2327","DOI":"10.1136\/bmj.g2327","article-title":"Meningitis B vaccine to be introduced in UK after U turn on its cost-effectiveness","volume":"348","author":"Wise","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jval.2020.06.018_bib38","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1542\/peds.2004-1475","article-title":"Administration of epinephrine for life-threatening allergic reactions in school settings","volume":"116","author":"McIntyre","year":"2005","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jval.2020.06.018_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.carpath.2009.06.005","article-title":"Cardiac disease and risk of sudden death in the young: the burden of the phenomenon","volume":"19","author":"Fishbein","year":"2010","journal-title":"Cardiovasc Pathol"},{"issue":"13","key":"10.1016\/j.jval.2020.06.018_bib40","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.296.13.1593","article-title":"Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program","volume":"296","author":"Corrado","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jval.2020.06.018_bib41","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jval.2019.07.010","article-title":"The Joint Committee on Vaccination and Immunisation\u2019s advice on extending human papillomavirus vaccination to boys: were cost-effectiveness analysis guidelines bent to achieve a politically acceptable decision?","volume":"22","author":"O\u2019Mahony","year":"2019","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520344016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:40Z","timestamp":1761096160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520344016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1098301520344016"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.06.018","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}